S&P 500   3,633.10 (+1.55%)
DOW   30,030.53 (+1.48%)
QQQ   294.18 (+1.31%)
AAPL   115.33 (+1.30%)
MSFT   212.85 (+1.30%)
FB   276.28 (+2.92%)
GOOGL   1,759.75 (+1.86%)
AMZN   3,119.21 (+0.67%)
TSLA   558.56 (+7.03%)
NVDA   520.10 (-1.05%)
BABA   278.46 (+3.09%)
CGC   26.83 (+8.54%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.21 (-0.12%)
T   29.22 (+2.10%)
NIO   53.93 (-2.62%)
F   9.41 (+6.21%)
ACB   9.04 (+25.91%)
NFLX   481.93 (+1.11%)
GILD   60.63 (+1.24%)
BA   219.41 (+3.73%)
DIS   151.15 (+3.54%)
S&P 500   3,633.10 (+1.55%)
DOW   30,030.53 (+1.48%)
QQQ   294.18 (+1.31%)
AAPL   115.33 (+1.30%)
MSFT   212.85 (+1.30%)
FB   276.28 (+2.92%)
GOOGL   1,759.75 (+1.86%)
AMZN   3,119.21 (+0.67%)
TSLA   558.56 (+7.03%)
NVDA   520.10 (-1.05%)
BABA   278.46 (+3.09%)
CGC   26.83 (+8.54%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.21 (-0.12%)
T   29.22 (+2.10%)
NIO   53.93 (-2.62%)
F   9.41 (+6.21%)
ACB   9.04 (+25.91%)
NFLX   481.93 (+1.11%)
GILD   60.63 (+1.24%)
BA   219.41 (+3.73%)
DIS   151.15 (+3.54%)
S&P 500   3,633.10 (+1.55%)
DOW   30,030.53 (+1.48%)
QQQ   294.18 (+1.31%)
AAPL   115.33 (+1.30%)
MSFT   212.85 (+1.30%)
FB   276.28 (+2.92%)
GOOGL   1,759.75 (+1.86%)
AMZN   3,119.21 (+0.67%)
TSLA   558.56 (+7.03%)
NVDA   520.10 (-1.05%)
BABA   278.46 (+3.09%)
CGC   26.83 (+8.54%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.21 (-0.12%)
T   29.22 (+2.10%)
NIO   53.93 (-2.62%)
F   9.41 (+6.21%)
ACB   9.04 (+25.91%)
NFLX   481.93 (+1.11%)
GILD   60.63 (+1.24%)
BA   219.41 (+3.73%)
DIS   151.15 (+3.54%)
S&P 500   3,633.10 (+1.55%)
DOW   30,030.53 (+1.48%)
QQQ   294.18 (+1.31%)
AAPL   115.33 (+1.30%)
MSFT   212.85 (+1.30%)
FB   276.28 (+2.92%)
GOOGL   1,759.75 (+1.86%)
AMZN   3,119.21 (+0.67%)
TSLA   558.56 (+7.03%)
NVDA   520.10 (-1.05%)
BABA   278.46 (+3.09%)
CGC   26.83 (+8.54%)
GE   10.42 (+3.48%)
MU   63.47 (-1.11%)
AMD   85.21 (-0.12%)
T   29.22 (+2.10%)
NIO   53.93 (-2.62%)
F   9.41 (+6.21%)
ACB   9.04 (+25.91%)
NFLX   481.93 (+1.11%)
GILD   60.63 (+1.24%)
BA   219.41 (+3.73%)
DIS   151.15 (+3.54%)
Log in
NASDAQ:EIGR

Eiger BioPharmaceuticals Stock Forecast, Price & News

$9.05
-0.49 (-5.14 %)
(As of 11/24/2020 03:03 PM ET)
Add
Compare
Today's Range
$9.01
Now: $9.05
$9.70
50-Day Range
$7.98
MA: $9.56
$10.96
52-Week Range
$4.55
Now: $9.05
$15.82
Volume30,016 shs
Average Volume431,657 shs
Market Capitalization$294.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.
Read More
Eiger BioPharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138
Employees28

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.86 per share

Profitability

Net Income$-70,250,000.00

Miscellaneous

Market Cap$294.41 million
Next Earnings Date3/12/2021 (Estimated)
OptionableNot Optionable
$9.05
-0.49 (-5.14 %)
(As of 11/24/2020 03:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eiger BioPharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

How has Eiger BioPharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Eiger BioPharmaceuticals' stock was trading at $6.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EIGR shares have increased by 33.0% and is now trading at $9.06.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Eiger BioPharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Eiger BioPharmaceuticals
.

What stocks does MarketBeat like better than Eiger BioPharmaceuticals?

Wall Street analysts have given Eiger BioPharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eiger BioPharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Eiger BioPharmaceuticals' next earnings date?

Eiger BioPharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Eiger BioPharmaceuticals
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.61) by $0.09.
View Eiger BioPharmaceuticals' earnings history
.

What price target have analysts set for EIGR?

3 equities research analysts have issued 1 year target prices for Eiger BioPharmaceuticals' shares. Their forecasts range from $28.00 to $32.00. On average, they expect Eiger BioPharmaceuticals' stock price to reach $30.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price.
View analysts' price targets for Eiger BioPharmaceuticals
.

Who are some of Eiger BioPharmaceuticals' key competitors?

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Who are Eiger BioPharmaceuticals' key executives?

Eiger BioPharmaceuticals' management team includes the following people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 56, Pay $862.03k)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Independent Director (Age 57, Pay $53.5k)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 39, Pay $461.98k)
  • Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 49, Pay $417.8k)
  • Dr. Evan Loh, CEO of Paratek Pharmaceuticals & Director (Age 61, Pay $56k)

What is Eiger BioPharmaceuticals' stock symbol?

Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.68%), Mangrove Partners (3.36%), Assenagon Asset Management S.A. (1.90%), State Street Corp (1.58%), P.A.W. Capital Corp (1.23%) and DAVENPORT & Co LLC (0.79%). Company insiders that own Eiger BioPharmaceuticals stock include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton and Thomas John Dietz.
View institutional ownership trends for Eiger BioPharmaceuticals
.

Which institutional investors are selling Eiger BioPharmaceuticals stock?

EIGR stock was sold by a variety of institutional investors in the last quarter, including Voss Capital LLC, JPMorgan Chase & Co., Connor Clark & Lunn Investment Management Ltd., Arrowstreet Capital Limited Partnership, Rock Creek Group LP, AQR Capital Management LLC, Morgan Stanley, and DAVENPORT & Co LLC.
View insider buying and selling activity for Eiger BioPharmaceuticals
.

Which institutional investors are buying Eiger BioPharmaceuticals stock?

EIGR stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., BlackRock Inc., Mangrove Partners, GSA Capital Partners LLP, P.A.W. Capital Corp, Towerview LLC, Massachusetts Financial Services Co. MA, and Zeke Capital Advisors LLC. Company insiders that have bought Eiger BioPharmaceuticals stock in the last two years include David A Cory, Eldon C Mayer III, Jeffrey S Glenn, Sriram Ryali, Stephana Eilene Patton, and Thomas John Dietz.
View insider buying and selling activity for Eiger BioPharmaceuticals
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eiger BioPharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $9.06.

How big of a company is Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals has a market capitalization of $294.74 million. The biotechnology company earns $-70,250,000.00 in net income (profit) each year or ($3.08) on an earnings per share basis. Eiger BioPharmaceuticals employs 28 workers across the globe.

What is Eiger BioPharmaceuticals' official website?

The official website for Eiger BioPharmaceuticals is www.eigerbio.com.

How can I contact Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.